Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$50.3 million.

  • Rocket Pharmaceuticals' Net Income towards Common Stockholders rose 2456.12% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 665.18%. This contributed to the annual value of -$258.7 million for FY2024, which is 535.48% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Net Income towards Common Stockholders of -$50.3 million as of Q3 2025, which was up 2456.12% from -$68.9 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$34.5 million for Q2 2021, and its period low was -$69.6 million during Q2 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' median Net Income towards Common Stockholders value was -$59.7 million (recorded in 2023), while the average stood at -$56.6 million.
  • Over the last 5 years, Rocket Pharmaceuticals' Net Income towards Common Stockholders had its largest YoY gain of 2736.39% in 2021, and its largest YoY loss of 7234.53% in 2021.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Net Income towards Common Stockholders stood at -$44.2 million in 2021, then tumbled by 50.8% to -$66.7 million in 2022, then rose by 10.59% to -$59.7 million in 2023, then dropped by 1.12% to -$60.3 million in 2024, then rose by 16.57% to -$50.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$50.3 million for Q3 2025, versus -$68.9 million for Q2 2025 and -$61.3 million for Q1 2025.